Quick Answer
Moleculin Biotech, Inc. reported Net Income Loss of -$33.56 million for the year ending 2025.
- Moleculin Biotech, Inc. showed a decrease of -28.8% in Net Income Loss from 2024 to 2025.
- This data is from Moleculin Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2015: -$224.3 thousand | Q1 2016: -$332.0 thousand | Q2 2016: -$739.0 thousand | Q3 2016: -$1.43 million | Q1 2017: -$329.0 thousand | Q2 2017: -$3.42 million | Q3 2017: -$2.87 million | Q1 2018: -$1.93 million | Q2 2018: -$5.13 million | Q3 2018: -$2.04 million | Q1 2019: -$4.04 million | Q2 2019: -$1.22 million | Q3 2019: -$4.15 million | Q1 2020: -$1.21 million | Q2 2020: -$10.11 million | Q3 2020: -$3.40 million | Q1 2021: -$4.45 million | Q2 2021: -$4.24 million | Q3 2021: -$4.38 million | Q1 2022: -$6.87 million | Q2 2022: -$6.78 million | Q3 2022: -$8.61 million | Q1 2023: -$7.92 million | Q2 2023: -$5.98 million | Q3 2023: -$5.61 million | Q1 2024: -$6.43 million | Q2 2024: -$6.02 million | Q3 2024: -$7.02 million | Q1 2025: -$5.90 million | Q2 2025: -$17.81 million | Q3 2025: -$25.40 million.
- Over the full 10 years of available data (2016 to 2025), Moleculin Biotech, Inc.'s Net Income Loss has declined by 754.8%.
- Historical annual values: Fiscal year 2025: -$33.56 million | Fiscal year 2024: -$26.05 million | Fiscal year 2023: -$29.77 million | Fiscal year 2022: -$29.03 million | Fiscal year 2021: -$15.89 million | Fiscal year 2020: -$17.36 million | Fiscal year 2019: -$13.21 million | Fiscal year 2018: -$11.88 million | Fiscal year 2017: -$9.81 million | Fiscal year 2016: -$3.93 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: